Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | STAT1 | P42224 | 1/20 | 0.52 |
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926045 | 0.89 | MAPT (0.67) | MAPTSMN1; SMN2KDM4EALDH1A1TP53 | |
| SCHEMBL6924792 | 0.84 | METAP2 (0.52) | MAPTSMN1; SMN2KDM4EALDH1A1TP53 | |
| SCHEMBL6926526 | 0.82 | MMP2 (0.57) | MAPTSMN1; SMN2KDM4ERAB9AALDH1A1 | |
| SCHEMBL6924788 | 0.81 | MAPT (0.52) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL6926001 | 0.81 | MAPT (0.52) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL6925493 | 0.81 | MAPT (0.48) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL6925468 | 0.81 | CBFB (0.53) | MAPTSMN1; SMN2KDM4ERAB9AALDH1A1 | |
| SCHEMBL6925486 | 0.80 | GRM4 (0.51) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL6925823 | 0.80 | MAPT (0.51) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL6925861 | 0.80 | GLO1 (0.47) | MAPTSMN1; SMN2ALDH1A1TP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184556-A1 | SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-07-19 | — | — | US | disclosed |
| US-20120184556-A1 | SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-07-19 | — | — | US | disclosed |
| US-20120184556-A1 | SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-07-19 | — | — | US | disclosed |
| WO-2011011722-A1 | SUBSTITUTED BENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS | VANDERBILT UNIVERSITY (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184556-A1 | SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS | GRM4, GRIK4, GRIA4 | MAPT 3868/4885SMN1; SMN2 2523/4885KDM4E 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.